Status:
UNKNOWN
Effect of Sevelamer on P-cresol Levels in CKD
Lead Sponsor:
Federico II University
Conditions:
Chronic Kidney Disease Stage 3-5
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The accumulation of p-cresol, a product of the metabolism of aromatic aminoacid operated by resident intestinal bacteria increases the cardiovascular risk of chronic kidney disease (CKD) patients. The...
Eligibility Criteria
Inclusion
- age \>18 years,
- CKD stage 3-5
Exclusion
- Existing or previous treatment within the last 1 year with a phosphate binder;
- hyperphosphatemia (\>5.6 mg/dL);
- hypophosphatemia (\<2.5 mg/dL);
- malnutrition,
- malignant neoplasms,
- current history of gastrointestinal and/or endocrine diseases.
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02199444
Start Date
June 1 2014
Last Update
February 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
federico II university, department of nephrology
Naples, Italy, Italy, 80131